Y-Type Meningitis Vaccine

The Y-Type Meningitis Vaccine is a product of AIM Persistence Biopharmaceutical Co., Ltd. As an experienced manufacturer and supplier with strong R&D capabilities, we can provide vaccine protection against Y-type meningococcal meningitis, and also offer a quadrivalent meningococcal vaccine that protects against four types with a single dose, simultaneously defending against A, C, and W135 types.

Injection Method and Dosage

The Y-Type Meningitis Vaccine is administered via subcutaneous injection at the deltoid muscle attachment site on the outer side of the upper arm.

To use, open the vaccine vial, add the specified amount of diluent for reconstitution, shake well, and use immediately.

For injection, one dose is given to children over 2 years old and adults, with a single dose of 0.5ml. Vaccination should be completed before the meningitis epidemic season.

Please note:

We recommend booster vaccinations for high-risk individuals in epidemic areas, especially children under 4 years old at the time of their first vaccination. If the high-risk status persists, a booster dose should be given 2 to 3 years after the initial immunization. Older children and adults whose antibody levels decline rapidly after vaccination should also consider a booster dose within 3 to 5 years after the initial immunization.

Case Study: Cases of Group Y Meningococcal Meningitis

A two-year-old boy

Diagnosis: Blood culture showed positive Y Meningococcus (cerebrospinal fluid culture was performed on the third day after antibiotic treatment and was negative).

Outcome: Underwent skin grafting surgery and was unable to walk

Immunization history: Received two doses of Group A meningococcal polysaccharide vaccine

Wang X, et al. Clinical and molecular characterization of the first culture-confirmed pediatric fulminant meningococcemia case caused by a serogroup Y clonal complex 23 strain in China. Vaccine. 2021 Jun 16:S0264-410X(21)00755-6